Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Breast cancer drug approvals by the US FDA from 1949 to 2018

  1. Chandra P. Leo

    1. HBM Partners, Zug, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Cornelia Leo

    1. Interdisciplinary Breast Center, Kantonsspital Baden, Baden, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Thomas D. Szucs

    1. European Center for Pharmaceutical Medicine, University of Basel, Basel, Switzerland.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Breast cancer is the most common malignancy diagnosed in women worldwide, and so the development of new drugs is an important priority. To better understand the evolution of new drug approvals for breast cancer, we analysed approvals of oncology drugs by the US Food and Drug Administration (FDA) during the 70-year period from 1949 (the year of the first oncology drug approval) to 2018 (see Supplementary Box 1 for details).

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 19, 11 (2020)

doi: https://doi.org/10.1038/d41573-019-00201-w

Acknowledgements

The authors thank A. Mollet at the European Center for Pharmaceutical Medicine, University of Basel, Switzerland, for her support.

Updates & Corrections

  • Correction 14 January 2020: The author affiliations in the pdf were incorrect. These have now been corrected in the online pdf.

Supplementary Information

  1. Supplementary Box 1
  2. Supplementary Tables

Competing Interests

C.P.L. is employed by HBM Partners, which invests in emerging biotech companies.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links